Article Details
Retrieved on: 2022-07-27 05:59:59
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
InflaRx plans to apply for Emergency Use Authorization from the US FDA in Q3/2022 for vilobelimab, the company's treatment for critically ill ...
Article found on: european-biotechnology.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here